In Brief: Delaney clause
This article was originally published in The Rose Sheet
Delaney clause: Senate Labor and Human Resources Committee "recognizes the importance" of Delaney clause reform, according to the committee report on the Senate FDA reform bill (S 1477), filed June 20. "Every recent FDA commissioner has supported reevaluation and revision of the Delaney clause to reflect more recent scientific and technical advances," the report states. Furthermore, the report notes, both FDA and EPA use quantitative risk assessment to regulate carcinogenic substances and have adopted a negligible cancer-risk standard rather than a zero-risk standard. Sen. Judd Gregg (R-N.H.) introduced an amendment to S 1477 reforming Delaney clause during mark-up of the bill by the committee, but withdrew it due to inadequate time to properly consider the matter...
You may also be interested in...
With a push from the Organic Consumers Association, the National Organic Standards Board is recommending that the use of nanotechnology be strictly prohibited from products certified under the National Organic Program
Though global market-size estimates differ, analysts at SupplySide West 2010 in Las Vegas agreed that cosmeceuticals remain a promising growth vehicle
Weekly Trademark Review